| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ANVSAnnovis Bio, Inc. | 84.81M | 3.20 | -0.00 | -189.15% | ||||
| CLNNClene Inc. | 60.19M | 5.11 | -0.90 | -47.71% | -142.5% | -17.38% | ||
| ABOSAcumen Pharmaceuticals, Inc. | 112.67M | 1.86 | -1.09 | -143.12% | 0.16 | |||
| BHVNBiohaven Ltd. | 1.58B | 11.92 | -1.28 | -198.83% | 0.09 | |||
| IKTInhibikase Therapeutics, Inc. | 200.09M | 1.65 | -1.42 | -100% | -65.37% | 0.00 | ||
| ALECAlector, Inc. | 198.66M | 1.82 | -1.48 | 3.6% | -156.03% | -186.68% | 0.34 | |
| CGTXCognition Therapeutics, Inc. | 121.82M | 1.38 | -1.62 | -76.61% | 0.04 | |||
| ATHEAlterity Therapeutics Limited | 60M | 3.31 | -2.90 | 35.32% | -330.63% | -73.75% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 8.27K | 25.34K | 67.98K | 110.37K | 97.92K | 103.17K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -8.27K | -25.34K | -67.98K | -110K | -97.92K | -103.17K | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | 0.99% | -2.07% | -1.68% | -0.62% | 0.11% | -0.05% | 1% | - | - | - |
| Operating Expenses | 6.4M | 14.85M | 11.28M | 11.92M | 11.45M | 15.87M | 24.68M | 3.48M | 7.81M | 18.23M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 2.52M | 8.59M | 6.19M | 6.17M | 4.83M | 6.44M | 7.45M | 2.14M | 6.52M | 9.17M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.88M | 6.25M | 5.09M | 5.75M | 6.62M | 9.43M | 8.5M | 1.34M | 8.44M | 18.8M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 8.73M | 0 | -7.14M | -9.74M |
| Operating Income | -6.41M | -14.87M | -11.35M | -12.03M | -11.55M | -15.97M | -24.68M | -3.48M | -7.81M | -18.23M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 0.13% | -1.32% | 0.24% | -0.06% | 0.04% | -0.38% | -0.54% | 0.86% | -1.25% | -1.33% |
| EBITDA | -6.4M | -14.85M | -11.28M | -11.92M | -11.45M | -15.87M | -24.58M | -5.8M | -7.81M | -18.23M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 0.06% | -1.32% | 0.24% | -0.06% | 0.04% | -0.39% | -0.55% | 0.76% | -0.35% | -1.33% |
| D&A (Non-Cash Add-back) | 8.27K | 25.34K | 67.98K | 110.37K | 97.92K | 103.17K | 93.42K | 0 | 0 | 0 |
| EBIT | -6.41M | -18.37M | 498.03K | -18.81M | -11.47M | -15.86M | -16.04M | -5.8M | -7.81M | -18.23M |
| Net Interest Income | -313K | 0 | 0 | 0 | 0 | 114.26K | 137.49K | 61.64K | 219.43K | 1.94M |
| Interest Income | 0 | 0 | 0 | 151.65K | 0 | 114.26K | 137.49K | 62.23K | 219.43K | 1.94M |
| Interest Expense | 313.12K | 29.69K | 2.92M | 0 | 0 | 0 | 0 | 587 | 0 | 0 |
| Other Income/Expense | -313K | -3.53M | 8.93M | -6.78M | 85.3K | 114.25K | 137.49K | -2.33M | 5.64M | 1.94M |
| Pretax Income | -6.72M | -18.4M | -2.42M | -18.81M | -11.47M | -15.86M | -24.54M | -5.8M | -2.17M | -16.29M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | -365K | -1.06M | -437K | 332.88K | -1.68M | -443.89K | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 0.98% | 0.56% | 0.98% | 1.03% | 0.89% | 0.98% | 1% | 1% | 1% |
| Net Income | -6.72M | -18.04M | -1.36M | -18.37M | -11.8M | -14.19M | -24.1M | -5.8M | -2.17M | -16.29M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 0.53% | -1.68% | 0.92% | -12.46% | 0.36% | -0.2% | -0.7% | 0.76% | 0.63% | -6.5% |
| Net Income (Continuing) | -6.72M | -18.04M | -1.36M | -18.37M | -11.8M | -14.19M | -24.1M | -5.8M | -2.17M | -16.29M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -28852.23 | -1982.96 | -120.35 | -424.93 | -131.95 | -22.50 | -18.51 | -11.20 | -0.82 | -2.02 |
| EPS Growth % | -1.56% | 0.93% | 0.94% | -2.53% | 0.69% | 0.83% | 0.18% | 0.39% | 0.93% | -1.46% |
| EPS (Basic) | -28852.23 | -1982.96 | -123.33 | -424.93 | -131.95 | -22.50 | -18.51 | -11.20 | -0.82 | -2.02 |
| Diluted Shares Outstanding | 233 | 9.1K | 11.34K | 43.23K | 89.42K | 717.76K | 1.3M | 518.14K | 2.66M | 8.07M |
| Basic Shares Outstanding | 233 | 9.1K | 11.06K | 43.23K | 89.42K | 717.76K | 1.3M | 518.14K | 2.66M | 8.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.04M | 1.6M | 9.67M | 8.91M | 14.65M | 18.78M | 37.82M | 4.16M | 9.96M | 43.08M |
| Cash & Short-Term Investments | 2M | 1.55M | 8.9M | 7.99M | 14.18M | 18.52M | 37.31M | 4.09M | 7.79M | 38.92M |
| Cash Only | 2M | 1.55M | 8.9M | 7.99M | 14.18M | 18.52M | 37.31M | 4.09M | 7.79M | 9M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29.92M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 915.4K | 2.25M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 233.48K | 15.88M | 16.48M | 9.29M | 9.63M | 8.95M | 15.58K | 0 | 7.77K | 0 |
| Property, Plant & Equipment | 52K | 79.75K | 460.65K | 350.28K | 499.41K | 298.36K | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 6.93M | 6.93M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.45M | 8.64M | 8.64M | 8.64M | 8.64M | 8.64M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 250K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -6.52M | 232.68K | 450.49K | 298.48K | 322.3K | 15.77K | 15.58K | 0 | 7.77K | 0 |
| Total Assets | 2.28M | 17.48M | 26.15M | 18.2M | 24.28M | 27.73M | 37.84M | 4.16M | 9.97M | 43.08M |
| Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -0.95% | 6.68% | 0.5% | -0.3% | 0.33% | 0.14% | 0.36% | -0.89% | 1.4% | 3.32% |
| Total Current Liabilities | 1.47M | 4.44M | 2.69M | 804.04K | 1.72M | 2.44M | 2.93M | 13.16M | 2.6M | 3.88M |
| Accounts Payable | 424.68K | 1.68M | 511.96K | 198.82K | 1.25M | 545.84K | 947.5K | 97.3K | 662.47K | 1.51M |
| Days Payables Outstanding | 18.75K | 24.26K | 2.75K | 657.5 | 4.66K | 1.93K | - | - | - | - |
| Short-Term Debt | 424.96K | 1.88M | 550K | 0 | 0 | 0 | 0 | 12.41M | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 38.03K | 151.33K | 30.84K | 92.11K | 175.82K | 35.36K | 65.94K | 50.32K | 1.11M | 919.08K |
| Current Ratio | 1.39x | 0.36x | 3.59x | 11.09x | 8.51x | 7.71x | 12.92x | 0.32x | 3.84x | 11.11x |
| Quick Ratio | 1.39x | 0.36x | 3.59x | 11.09x | 8.51x | 7.71x | 12.92x | 0.32x | 3.84x | 11.11x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 846.91K | 3.86M | 2.23M | 1.79M | 2.42M | 479.59K | 0 | 0 | 0 | 0 |
| Long-Term Debt | 818.65K | 550K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 135.57K | 35.69K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 3.28M | 2.22M | 1.79M | 2.29M | 443.89K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 28.27K | 31.91K | 1.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.32M | 8.3M | 4.92M | 2.59M | 4.14M | 2.92M | 2.93M | 13.16M | 2.6M | 3.88M |
| Total Debt | 1.24M | 2.43M | 550K | 0 | 247.04K | 149.16K | 0 | 12.41M | 0 | 0 |
| Net Debt | -753.58K | 877.15K | -8.35M | -7.99M | -13.93M | -18.37M | -37.31M | 8.32M | -7.79M | -9M |
| Debt / Equity | - | 0.26x | 0.03x | - | 0.01x | 0.01x | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -20.46x | -500.98x | -3.89x | - | - | - | - | -5920.84x | - | - |
| Total Equity | -41.62K | 9.18M | 21.23M | 15.61M | 20.13M | 24.81M | 34.91M | -9M | 7.38M | 39.2M |
| Equity Growth % | -1% | 221.66% | 1.31% | -0.26% | 0.29% | 0.23% | 0.41% | -1.26% | 1.82% | 4.31% |
| Book Value per Share | -178.73 | 1009.86 | 1872.46 | 361.13 | 225.17 | 34.57 | 26.81 | -17.37 | 2.77 | 4.86 |
| Total Shareholders' Equity | -41.62K | 9.18M | 21.23M | 15.61M | 20.13M | 24.81M | 34.91M | -9M | 7.38M | 39.2M |
| Common Stock | 8.12K | 10.35K | 968 | 3.38K | 33.48K | 64.02K | 2.04K | 518 | 5.67K | 8.7K |
| Retained Earnings | -42.15M | -60.19M | -61.55M | -79.92M | -91.72M | -105.91M | -130.01M | -52.27M | -54.44M | -70.73M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 56.2K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.19M | -10.77M | -12.33M | -10.77M | -9.86M | -13.55M | -14.5M | -2.57M | -7.45M | -16.53M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 0.43% | -1.08% | -0.15% | 0.13% | 0.08% | -0.37% | -0.07% | 0.82% | -1.9% | -1.22% |
| Net Income | -6.72M | -18.04M | -1.36M | -18.37M | -11.8M | -14.19M | -24.1M | -5.8M | -2.17M | -16.29M |
| Depreciation & Amortization | 8.27K | 25.34K | 67.98K | 110.37K | 97.92K | 103.17K | 93.42K | 0 | 0 | 0 |
| Stock-Based Compensation | 594.17K | 0 | 0 | 0 | 0 | 736.12K | 897.26K | 0 | 407.63K | 1.41M |
| Deferred Taxes | 0 | -364.8K | -1.06M | -437.29K | 332.88K | -1.68M | -443.89K | 0 | 0 | 0 |
| Other Non-Cash Items | 313.61K | 6.35M | -5.85M | 8.7M | 515.38K | 0 | 8.69M | 2.85M | -5.42M | -1.21M |
| Working Capital Changes | 617.85K | 1.31M | -2.33M | -276.94K | 994.44K | 1.47M | 356.37K | 379.94K | -261.36K | -440.66K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -915.4K | -1.34M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 647.58K | 0 | -1.66M | -275.83K | 567.67K | 950.6K | 605.37K | 79.15K | 565.17K | 848.97K |
| Cash from Investing | 2.46M | 8.5M | -447.82K | 0 | 0 | 0 | 4K | 0 | 0 | -28.66M |
| Capital Expenditures | -40.29K | -2.33K | -447.82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.39M | 1.83M | 20.12M | 9.87M | 16.04M | 17.89M | 33.3M | 0 | 11.15M | 46.4M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -15.31K | 0 | -125.98K | -428.54K | 3.73M | 7.06M | -3.8M | 0 | 10.34M | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -5.23M | -10.77M | -12.78M | -10.77M | -9.86M | -13.55M | -14.5M | -2.57M | -7.45M | -16.53M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 0.42% | -1.06% | -0.19% | 0.16% | 0.08% | -0.37% | -0.07% | 0.82% | -1.9% | -1.22% |
| FCF per Share | -22438.72 | -1184.23 | -1127.20 | -249.20 | -110.25 | -18.88 | -11.14 | -4.97 | -2.80 | -2.05 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.60x | 9.03x | 0.59x | 0.84x | 0.96x | 0.60x | 0.44x | 3.43x | 1.01x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -35.25% | -394.55% | -8.98% | -99.72% | -66.02% | -63.12% | -80.69% | -44.79% | -29.44% | -69.95% |
| Return on Invested Capital (ROIC) | -62.05% | -240.73% | -74.19% | -88% | -125.34% | -189.4% | -914.95% | - | - | -91.79% |
| Debt / Equity | - | 0.26x | 0.03x | - | 0.01x | 0.01x | - | - | - | - |
| Interest Coverage | -20.46x | -500.98x | -3.89x | - | - | - | - | -5920.84x | - | - |
| FCF Conversion | 0.77x | 0.60x | 9.03x | 0.59x | 0.84x | 0.96x | 0.60x | 0.44x | 3.43x | 1.01x |
CervoMed Inc. (CRVO) reported $0.3M in revenue for fiscal year 2024. This represents a 43% decrease from $0.6M in 2011.
CervoMed Inc. (CRVO) grew revenue by 0.0% over the past year. Growth has been modest.
CervoMed Inc. (CRVO) reported a net loss of $25.6M for fiscal year 2024.
CervoMed Inc. (CRVO) has a return on equity (ROE) of -69.9%. Negative ROE indicates the company is unprofitable.
CervoMed Inc. (CRVO) had negative free cash flow of $24.9M in fiscal year 2024, likely due to heavy capital investments.